Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect Lexeo Therapeutics to post earnings of ($0.80) per share for the quarter.
Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, topping analysts' consensus estimates of ($0.87) by $0.09. On average, analysts expect Lexeo Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Lexeo Therapeutics Stock Down 1.5 %
Shares of NASDAQ LXEO traded down $0.07 during mid-day trading on Friday, reaching $4.64. 1,263,282 shares of the company traded hands, compared to its average volume of 437,477. The company's fifty day moving average is $3.01 and its two-hundred day moving average is $5.44. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. Lexeo Therapeutics has a fifty-two week low of $1.45 and a fifty-two week high of $19.50. The stock has a market cap of $154.03 million, a PE ratio of -1.47 and a beta of 1.52.
Analyst Ratings Changes
A number of equities analysts have recently commented on LXEO shares. Chardan Capital dropped their price target on shares of Lexeo Therapeutics from $25.00 to $22.00 and set a "buy" rating on the stock in a research report on Tuesday, April 8th. Leerink Partners dropped their target price on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a report on Monday, March 24th. Royal Bank of Canada decreased their price target on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a report on Tuesday, March 25th. Finally, HC Wainwright reiterated a "buy" rating and issued a $23.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday, April 8th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Lexeo Therapeutics currently has a consensus rating of "Buy" and an average price target of $22.20.
Read Our Latest Stock Analysis on Lexeo Therapeutics
About Lexeo Therapeutics
(
Get Free Report)
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
Recommended Stories
Before you consider Lexeo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexeo Therapeutics wasn't on the list.
While Lexeo Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
